Growth is also driven by the rise of telehealth consultations and digital prescriptions, enabling easier patient access to GLP-1 therapies without visiting physical stores
Medicines and Healthcare Regulatory Agency (MHRA) (2026) GLP-1 medicines for weight loss and diabetes: what you need to know, GOV.UK
Critical structural requirements Beyond dosage, the studies revealed critical structural requirements for BRP activity
A Brave New World: Therapeutic Area Deep Dives on Obesity This blog is the first of a new series exploring a range of topics in the obesity market, including: market size and scope, impact of payer controls, activity in non-traditional channels, patient behavior, GLP-1 impact, HCP responses, the policy landscape, pharmacy economics, and the outlook for the future of GLP-1